NK:IO, a startup working on natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised an additional £1.2M in funding to advance its work. This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing its differentiated NK cell therapy candidates into development. The £3.2M…
